Enzymatica AB (publ)
Stockholm Stock ExchangeTotal Valuation
Enzymatica AB (publ) carries a market capitalization of 609.27M, placing it among publicly traded companies globally. Its enterprise value stands at 537.78M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 609.27M |
| Enterprise Value | 537.78M |
Share Statistics
Enzymatica AB (publ) currently has 242.74M shares outstanding.
| Shares Outstanding | 242.74M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | 11.56 |
| PB Ratio | N/A |
| P/TBV Ratio | 7.40 |
| P/FCF Ratio | -9.08 |
| P/OCF Ratio | -9.08 |
Enterprise Valuation
| EV / Sales | 10.69 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Enzymatica AB (publ) maintains a current ratio of 15.05, meaning it holds 15.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.11, indicating moderate leverage, while an interest coverage ratio of -38.02 demonstrates limited ability to service its debt obligations.
| Current Ratio | 15.05 |
| Quick Ratio | 9.18 |
| Debt / Equity | 1.11 |
| Debt / EBITDA | -0.03 |
| Interest Coverage | -38.02 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -39.12 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.11 |
Taxes
| Income Tax | 59,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Enzymatica AB (publ)'s stock has declined approximately -12.23776% over the past 52 weeks. The 50-day moving average sits at 2.55, while the 200-day moving average is 2.23.
| Beta (5Y) | N/A |
| 52-Week Price Change | -12.23776% |
| 50-Day Moving Average | 2.55 |
| 200-Day Moving Average | 2.23 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Enzymatica AB (publ) generated 50.29M in revenue and converted that into -52.98M in net income, yielding earnings per share of -0.23. EBITDA reached -53.04M, while operating income came in at -53.04M.
| Revenue | 50.29M |
| Gross Profit | 33.25M |
| Operating Income | -53.04M |
| Pretax Income | -52.93M |
| Net Income | -52.98M |
| EBITDA | -53.04M |
| EBIT | -53.04M |
| Earnings Per Share (EPS) | -0.23 |
Balance Sheet
Enzymatica AB (publ) holds 45.29M in cash and equivalents against 1.59M in total debt, resulting in a net debt position of -45.29M.
| Cash & Cash Equivalents | 45.29M |
| Total Debt | 1.59M |
| Net Debt | -45.29M |
| Equity (Book Value) | N/A |
| Book Value Per Share | N/A |
| Working Capital | 69.27M |
Cash Flow
Enzymatica AB (publ) produced -64.07M in operating cash flow over the past twelve months.
| Operating Cash Flow | -64.07M |
| Capital Expenditures | N/A |
| Free Cash Flow | -64.07M |
| FCF Per Share | -0.28 |
Margins
Enzymatica AB (publ) operates with a gross margin of 66.13, reflecting its pricing power and cost economics. The operating margin of -105.48 and net profit margin of -105.36 provide insight into operational efficiency.
| Gross Margin | 66.13 |
| Operating Margin | -105.48 |
| Pretax Margin | -105.25 |
| Profit Margin | -105.36 |
| EBITDA Margin | -105.48 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -17.44 |
| FCF Yield | -11.02 |
Scores
Enzymatica AB (publ) posts an Altman Z-Score of 31.37, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 31.37 |